Leading international law firm Herbert Smith Freehills has advised Huatai Financial Holdings (Hong Kong) Limited as the sole sponsor of biopharmaceutical company Shanghai Bio-heart Biological Technology Co. Ltd. (02185.HK)’s mainboard listing on the Stock Exchange of Hong Kong.

Shanghai Bio-heart produces interventional cardiovascular devices, focusing on bioresorbable scaffold (BRS) and renal denervation (RDN) therapies.

Shanghai Bio-heart was listed on 23 December 2021.

"We are delighted to have worked with Shanghai Bio-heart, one of the leading interventional cardiovascular device specialists on its successful listing on the HKEX," said Hong Kong partner Matt Emsley. “The company is dedicated to developing medical devices to address the unmet medical needs of vascular disease and hypertension patients in China."

Herbert Smith Freehills has advised on a number of biotech listings since the Hong Kong exchange introduced its new regime for biotech listings in 2018, including those of Shanghai Junshi Biosciences (01877.HK), TOT BIOPHARM (01875.HK), SinoMab BioScience Limited (03681.HK), Peijia Medical (09996.HK), Antengene Corporation Limited (06996.HK), CARsgen Therapeutics (02171.HK), Brii Biosciences (02137.HK), Shanghai HeartCare Medical Technology (06609.HK), Acotec Scientific Holdings Limited (06669.HK), and Abbisko Cayman Limited (02256.HK).

"This is just the largest high-profile capital market transaction by a Chinese biotech company on which we have advised,” said Herbert Smith Freehills Kewei joint operation partner Stanley Xie. "We congratulate Shanghai Bio-heart on this successful IPO."

The China BRS product market was valued at US$0.2 billion in 2019, is expected to reach US$6.6 billion in 2030 at a CAGR of 38.5%. The China RDN product market is expected to reach RMB10.5 billion in 2030, after receiving approval from China's National Medical Products Administration.

Matt and Stanley jointly led the team advising the sole sponsor, assisted by of counsel Jin Kong, senior associate Jaime Fong, associates Angela Yuen, Sean Ji and Bryan Cheung, legal manager Hilary Chong and legal assistants Kate Lam and Ye Han.

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Alternative Legal Services business to provide high-efficiency solutions for verification and other document-intensive processes during the offering, assisted by legal analysts Shawna Peng and Jean Zhou.

全球领先的律师事务所史密夫斐尔作为生物制药公司上海百心安生物技术股份有限公司（02185.HK）独家保荐人华泰国际的境外律师，为其在香港联交所主板上市提供法律服务。

百心安从事介入式心血管装置，专注全降解支架（BRS）及肾神经阻断（RDN）疗程。

百心安于2021年12月23日开始在香港联交所交易。

史密夫斐尔香港办公室合伙人艾迈修（Matt Emsley）表示：“百心安是介入式心血管装置领域的龙头公司之一，致力于解决中国血管疾病及高血压患者的未获满足医疗需求，我们非常荣幸为其在联交所上市提供助力。”

自联交所于2018年放宽生物技术公司上市条件以来，史密夫斐尔已为多家公司在港上市提供法律服务，包括君实生物（01877.HK）、东曜药业（01875.HK）、中国抗体（03681.HK）、沛嘉医疗（09996.HK）、德琪医药（06996.HK）、科济药业（02171.HK）、腾盛博药（02137.HK）、心玮医疗科技（06609.HK）、先瑞达医疗（06669.HK）以及和誉开曼（02256.HK）。

科伟史密夫斐尔联营办公室合伙人谢守德表示：“这是本所近期服务的又一笔中国生物科技公司登陆香港资本市场的交易。衷心向百心安表示祝贺。”

2019年，中国全降解支架（BRS）产品市场规模为2亿美元，预计到2030年将以38.5%的复合年增长率达到66亿美元。在获得国家药监局批准后，预计2030年中国肾神经阻断（RDN）产品市场将达到105亿元人民币。

合伙人艾迈修和谢守德率领律师团队为此次上市独家保荐人提供法律服务。主要团队成员包括香港办公室资深顾问孔瑾、方靖颐（Senior Associate）、阮颖欣（Associate）、季晓源（Associate）、张皓阳（Associate）、种欢子（Legal Manager）、林乐彤（Legal Assistant）和叶晗（Legal Assistant）。

金燊（Legal Manager）率领的科伟史密夫斐尔联营办公室替代性法律服务（ALT）联合团队在发行期间为招股书验证及其他文件密集型工作提供高效率的解决方案，主要成员包括彭祺程（Legal Analyst）和周雅菁（Legal Analyst）。